Clinical Trials Browser

Phase 1/2 × fedratinib × 90 days × Clear all

NCT04817007 2026-05-08

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

Phase 1/2 Active not recruiting

Primary Myelofibrosis